Novavax Inc. closed 60.47% below its 52-week high of $17.81, which the company achieved on July 26th.

The U.S. Centers for Disease Control and Prevention has ended its emergency response to the H5N1 bird flu outbreak, a move ...

The stock's fall snapped a three-day winning streak.

The FDA's Dr. Vinay Prasad said that he disagreed with the agency's career vaccine reviewers about COVID shot approvals.

Major health groups sue HHS and Robert F. Kennedy Jr. over COVID-19 vaccine policy changes for children and pregnant ...

Novavax (NVAX) closed the most recent trading day at $6.61, moving -2.79% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.79% for the day. At the ...

Writing in JAMA, four former government officials warn that the Trump administration’s involvement in delaying the approval ...

Novavax (NVAX) closed at $6.36 in the latest trading session, marking a -2.15% move from the prior day. This move lagged the ...

The US Food and Drug Administration’s top vaccine official overrode agency experts in May to recommend against the broad use ...

Federal documents show he disagreed with conclusions the benefits outweighed the risk of side effects, which are rare.

FDA vaccine head Vinay Prasad restricted Moderna and Novavax COVID vaccines to high-risk groups, overriding staff advice amid ...

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...